E merging efforts in precision oncology are largely predicated on the identification of 'actionable' oncogene mutations, whose pharmacological inhibition elicits oncogene addiction . First, multiple studies 3 have shown that most adult malignancies lack actionable mutations or harbor mutations either in non-druggable oncogenes (for example, RAS and MYC family proteins) or in genes of poorly characterized therapeutic value 4 . Moreover, while mutation-directed therapy often achieves a remarkable initial response, this is almost inevitably followed by relapse and emergence of drug resistance 5, 6 . Finally, analysis of hundreds of cell lines and compounds shows that, with some exceptions-such as for BRAF, ERBB2, EGFR and ALK1 inhibitors-mutations are poor predictors of drug sensitivity 7 . This is not entirely surprising, as drug sensitivity is a complex (dynamic, multifactorial, polygenic) phenotype. As such, there is urgent need for novel approaches that complement and extend oncogene addiction.
1
. Despite initial successes and clinical deployment of this concept, several limitations have emerged 2 . First, multiple studies 3 have shown that most adult malignancies lack actionable mutations or harbor mutations either in non-druggable oncogenes (for example, RAS and MYC family proteins) or in genes of poorly characterized therapeutic value 4 . Moreover, while mutation-directed therapy often achieves a remarkable initial response, this is almost inevitably followed by relapse and emergence of drug resistance 5, 6 . Finally, analysis of hundreds of cell lines and compounds shows that, with some exceptions-such as for BRAF, ERBB2, EGFR and ALK1 inhibitors-mutations are poor predictors of drug sensitivity 7 . This is not entirely surprising, as drug sensitivity is a complex (dynamic, multifactorial, polygenic) phenotype. As such, there is urgent need for novel approaches that complement and extend oncogene addiction.
Recent results on the aberrant regulatory logic of cancer-related phenotypes have highlighted the existence of master regulator proteins, whose coordinated activity within tightly regulated modules (tumor checkpoints) is strictly necessary for tumor state initiation and maintenance 8 . Consistently, as shown in leukemia 9 , lymphoma 10, 11 , glioblastoma 12 , prostate 13, 14 , neuroblastoma 15 and breast cancer 16 , genetic or pharmacological inhibition of master regulator proteins leads to tumor-checkpoint collapse and loss of tumor viability. Indeed, master regulators are highly enriched in essential 10 and synthetic-lethal [11] [12] [13] 16 proteins, thus representing a novel class of non-oncogene dependencies 17, 18 and pharmacological targets. Their mechanistic role in tumor cell state maintenance results from their mechanistic transcriptional control of gene expression signatures (GES) representing the tumor cell's transcriptional identity. Master regulator proteins can be efficiently and systematically elucidated using the MARINa (Master Regulator Inference algorithm) 12, 19 and VIPER (Virtual Proteomics by Enriched Regulon analysis) 20 algorithms-the latter allowing analysis on an individual sample basis, a prerequisite for precision oncology applications. These algorithms were extensively validated [11] [12] [13] 16, 21 . Thus, the rationale for this methodology (OncoTreat) is that small-molecule compounds capable of inducing tumor-checkpoint , Laura H. Tang   3 , Adina Grunn 1 . Both can be systematically identified by analyzing large, tumor-specific gene expression profile data sets using the algorithm for the accurate reconstruction of cellular networks (ARACNe) 26, 27 , as supported by extensive experimental validation studies 12, 13, 19, 28 . Alternative reverse engineering algorithms, such as CLR or CellNet 29, 30 , producing high-accuracy transcriptional interaction maps may also be used and could be explored in follow-up studies.
Analysis of 212 GEP-NET RNA-Seq profiles yielded an interactome comprising 571,499 transcriptional interactions between 5,631 proteins-including 1,785 transcriptional regulators and 3,846 signaling proteins (Methods)-and 20,136 target genes. Benchmark tests confirmed the GEP-NET interactome optimality to analyze GEP-NET samples and its distinct nature from 25 tumor-specific models previously generated and validated by our laboratory (Supplementary Table 3 and Supplementary Fig. 1b) . Moreover, using all GEP-NET samples for interactome generation, rather than subtype-specific samples, maximized prediction quality, as measured by overall regulon enrichment in GEP-NET metastatic progression signatures ( Supplementary Fig. 1b ). In addition, regulons from the resulting pan-GEP-NET interactome were highly conserved with those of subtype-specific interactomes (at a false discovery rate (FDR) < 0.05) 13 , including for metastases (99% conservation), primary tumors (98.9%), P-NETs (97.2%) and SI-NETs (94.5%) ( Supplementary Fig. 1c,d ).
GEP-NET molecular subtypes. Unsupervised analysis of GEP-
NET transcriptional profiles highlighted a strong tissue-of-origin contribution. Specifically, on the basis of principal component analysis, the first five components accounted for 33% of the total sample variance and clustered with primary tumor site, regardless of whether samples were derived from primaries, lymph nodes or metastases ( Supplementary Fig. 2a ). This observation was further confirmed based on a t-distributed stochastic neighbor embedding (t-SNE) projection of GEP-NET transcriptomes in two dimensions ( Supplementary Fig. 2b ). Consistently, partitioning around medoids (PAM)-based consensus clustering, followed by cluster reliability analysis (Methods), suggested optimal sample partitioning into four distinct clusters (E1-E4) that mostly co-segregated with primary tumor site ( Fig. 1a and Supplementary Fig. 2d ). Clusters E1-E3 were highly enriched in SI-NET, P-NET and RE-NET samples, respectively. Only cluster E4 was mixed, including samples from SI-NETs and P-NETs.
VIPER-inferred protein activity represents a more reproducible biomarker than gene expression 20 : first, protein activity represents a more mechanistic cell state determinant because it reflects causal regulation of tumor signature genes; second, activity of each protein is inferred from expression of tens to hundreds of transcriptional targets, thus averaging out measurement noise and improving reproducibility 20 ; third, bias and technical noise that are inconsistent with the regulatory model are effectively eliminated. We thus used VIPER to transform 212 GEP-NET transcriptional profiles into protein-activity profiles, representing sample-specific activity of 5,578 proteins 20 . As expected 8 , protein activity significantly outperformed gene expression-based clustering (P < 10
, by onesided paired U-test comparison of single-sample cluster reliability scores, Supplementary Fig. 2d-i) .
Unsupervised PAM-based consensus cluster analysis and t-SNE analysis of VIPER-inferred protein activity identified five clusters (A1-A5) representing molecularly distinct GEP-NET subtypes ( Fig. 1b and Supplementary Fig. 2c ). These included a SI-NETspecific cluster (A1, yellow), a P-NET specific cluster (A3, blue), a RE-NET cluster (A4, red) and two heterogeneous clusters including mainly P-NET and SI-NET samples (A2, green; A5: purple; Fig. 1b and Supplementary Fig. 2c ). We used a matched color scheme to represent cluster membership in the t-SNE projection, which showed essentially an equivalent cluster structure identified by both unsupervised analyses (adjusted Rand index = 0.88, P < 10
by permutation test, Fig. 1b and Supplementary Fig. 2c ). Moreover, on the basis of expression of established markers, P-NETs were better divided across three distinct clusters, consistent with potential cell of origin, including gastrinoma and insulinoma (green), glucagonoma (blue) and non-secretory P-NETs (purple) (Fig. 1) . These results confirm strong tissue-lineage-specific (epigenetic) memory, independent of tumor stage.
Elucidating master regulators of metastatic GEP-NET state. The normal tissue counterpart of GEP-NET malignancies is the subject of significant debate 31 . In addition, before metastatic progression, these tumors have favorable prognosis 25 . Thus, rather than seeking master regulators controlling transformation from normal to TFEC  IKZF1  SPI1  MNDA  CD86  ISX  HDGF  CAP1  MYCL1  C11orf9  CAND2  TRAK1  LCORL  KHDRBS3  PRKCD  CRY2  KIF13B  DCAF6  LRRFIP1  CRYM  ERBB3  ZNF77  TP53BP1  ZSCAN22  FGG  LBP  LHX2  ADRA1A  LECT2  GDF2  CCL16  CUX2  BMP10  KNG1  TBX20  NR1I3  RIPPLY1  ONECUT1  NR1H4  CXCL2  TNFSF14  ADH1A  AMBP  APOA1  CREB3L3  SEC14L2  JUB  LIN54  SEBOX  CEACAM1  F7 tumor-related NET-cell state, we focused on master regulators representing mechanistic determinants of progression from primary to metastatic disease, similar to ref. 21 . To elucidate these candidate dependencies, we performed VIPER analysis of gene expression signatures representing transitions between primary tumors and hepatic metastases (MET-GES)-representing 69 of the 82 metastatic samples-using the GEP-NET interactome.
To address the potential heterogeneity of tumor progression mechanisms and to support use of this framework in precision oncology, each hepatic metastasis was analyzed on an individual basis (Supplementary Table 2 ). Ideally, each metastasis would be compared to its patient-matched primary 21 . However, since patientmatched samples were not available for this rare malignancy, MET-GES signatures were generated by differential expression analysis (z-score based) of each hepatic metastasis in an activity-based cluster (A1-A5) against the average of all primary samples in that cluster (Fig. 1b) . Three primary samples were discarded, including a P-NET and two SI-NETs, since they could not be reliably clustered (one-tailed cluster reliability FDR > 0.01). Candidate master regulators were then inferred by VIPER analysis of these signatures, using the GEP-NET interactome. Comparing metastases to cluster-matched primaries effectively discounts lineage determinants, which would otherwise represent confounding factors leading to contamination of metastatic progression master regulators with lineage master regulators.
Inferred master regulators were surprisingly conserved across patients, both inter and intra cluster, suggesting a common metastatic progression mechanism. Indeed, the 25 most statistically significant positive and negative VIPER-inferred master regulators of each sample were highly enriched in proteins that were differentially active in most other metastatic samples, with 1,416 of 2,346 possible metastatic sample pairs showing statistically significant master regulator overlap (FDR < 0.01, by enrichment analysis, Fig. 1c and Supplementary Fig. 3a ). Consensus clustering identified four clusters (M1-M4) representing distinct metastatic progression mechanisms (Fig. 1c) , as well as several master regulators shared by most metastatic samples, such as the developmental proteins GDF2, CUX2 and BMP10 (Fig. 1d) . A comprehensive heatmap representing the most conserved master regulators across all clusters is provided in Supplementary Table 4a-e.
Not surprisingly, since progression signatures were based on cluster-matched metastatic and primary samples, there was minimal association between the five GEP-NET subtype clusters (A1-A5) and the four metastatic progression clusters (M1-M4), with A1 and A4 samples preferentially clustering in M5 (SI-NET enriched) and M1 (RE-NET enriched), respectively. This confirms an effective control of lineage-related confounding factors and suggests that GEP-NETs may share common metastatic progression mechanisms, largely decoupled from primary tumor site and subtype identity.
Validation of master regulators by shRNA silencing. Effective validation of candidate master regulators requires cell lines or mouse models that most closely recapitulate their VIPER-inferred activity 15 . We thus considered 921 cell lines comprising the Cancer Cell Line Encyclopedia 32 , as well as two GEP-NET-derived cell lines (H-STS 33 and KRJ-I 34 ), both isolated from SI-NET patients. For each cell line, a putative metastatic progression signature was generated by differential expression with the profile of a primary GEP-NET-derived cell line (P-STS 33 ). Cells were scored on the basis of the consistency of their gene expression profiles with the patient-derived GEP-NET interactome ( Supplementary  Fig. 4a ) and on the enrichment of their differentially active proteins in master regulators of metastatic GEP-NET samples (Fig. 2, Supplementary Fig. 4 and Supplementary Note). H-STS and KRJ-1-the 4th (top 0.43%) and 6th (top 0.65%) best matched models out of 923 available ones, respectively ( Supplementary   Fig. 4c,d )-were selected, given their GEP-NET origin and propensity to implant in xenograft models.
We then proceeded to validate master regulators that were aberrantly active both across metastatic patients and in H-STS cells. We found 55 candidate master regulators showing significant differential activity (P < 10 -4 by enrichment analysis, Bonferroni corrected, using the aREA algorithm 20 , Supplementary Fig. 3c ). Of these, the top 34 most significant ones (P < 2.0 × 10 -7 , Bonferroni corrected) were prioritized for experimental validation (Supplementary Table 5) . Surprisingly, despite a very high tumor purity, several prioritized master regulators were immune cell markers. We thus confirmed their expression in H-STS cells by FACS analysis (Fig. 3 and Supplementary Note), suggesting that they were not identified as part of tumor immune infiltrate.
To assess whether master regulator proteins identified by our analysis represent critical tumor dependencies, we measured H-STS cell viability following their lentivirus-mediated shRNA silencing. Of 34 master regulators selected for validation, 16 could be reproducibly silenced (≥ 40%, based on quantitative PCR with reverse transcription (qRT-PCR)), by at least two independent shRNA hairpins ( Supplementary Fig. 3d ). Of these, 15 (94%) significantly reduced H-STS growth/viability in vitro (≥ 20%, one-tailed P < 0.01, by analysis of variance (ANOVA); Fig. 4 ), confirming their role as relevant tumor dependencies. These results were recapitulated in KRJ-I cells but not in the negative control cell line (NCI-H716) (Supplementary Figs. 3e and 6f). These results support the more universal (mutation-independent) nature of patient-specific master regulator dependencies discovered by this approach.
Validated master regulators include early neuroendocrine lineage factors (IKZF1, IKZF3, SPI-1, GFI-1 and POU2F2), EMT drivers (Notch2, EOMES and GATA3) and immunomodulatory factors (CD45 also known as PTPRC, IL2RB1, CD53, CD86, RUNX3, CIITA and IL10). Taken together, the concerted activity of these proteins recapitulates key hallmarks of aggressive neuroendocrine tumors and provides a compelling mechanistic portrait of the programs that are necessary to maintain GEP-NET cell state ( Fig. 4c and Supplementary Note).
Inference of master regulator activity inhibitors. To identify small-molecule compounds that could invert the activity of metastatic GEP-NET master regulators, we profiled a library of 504 compounds. These had been previously analyzed at the Broad Institute (Cambridge, MA, USA) for differential activity against a panel of 242 genomically characterized cancer cell lines and results for a subset of 354 of them had been previously published 7 . All 504 compounds were re-screened in available GEP-NET, patient-derived cells lines, including H-STS, P-STS and KRJ-I, and in NCI-H716 as a negative control. This led to the selection of 107 compounds-102 of which were commercially available-that were differentially active in GEP-NET-related cells, as measured by the area under the dose-response curve (AUC). Dose-response curves generated by the high-throughput screening facility at Columbia University and by the Broad Institute were compared. Overall, these data presented high reproducibility, with AUC-based Spearman correlation of 0.71. An additional five compounds were identified by literature analysis as direct master regulator inhibitor-including bafetinib, crizotinib, PHA-665752, SU11274 and Y-27632-for a total of 107 compounds (Supplementary Table 6 ).
To assess the ability of these compounds to induce tumor-checkpoint collapse (that is, global reversion of patient-specific master regulators), we generated gene expression profiles of H-STS cells at 24 h following perturbation with each compound at two sublethal concentrations, the 72 h effective dose 20 (ED 20 ) and one-tenth of that concentration and with control media (DMSO), in duplicate. Profiles were obtained by 30M SE read Illumina TruSeq sequencing of purified RNA from treated cells. This allows testing of the highest non-toxic compound concentration, thus focusing the analysis on compound mechanism of action (MoA) rather than on mechanisms of cell stress/death. We reasoned that, while in vivo endpoint phenotypes (tumor viability) are not effectively recapitulated in two-dimensional culture conditions, compound MoA is reasonably well recapitulated in both contexts and is most frequently assessed in vitro. We thus aimed to identify compounds capable of inverting master regulator signature activity in a closely related in vitro model of the patient-specific tumor, to prioritize compounds with potential in vivo activity.
Drug response signatures were generated by differential expression analysis of H-STS cells treated with each compound versus control media and further analyzed by VIPER to assess compoundmediated changes in protein activity. This prioritized all 5,602 regulatory proteins represented in the GEP-NET interactome, from the most inhibited to the most activated by each treatment, thus allowing identification of compounds capable of inducing highly statistically significant reversal of the master regulator-activity signature in each sample (tumor-checkpoint collapse). For each sample, this was accomplished by assessing the enrichment of its top 50 positive and 50 negative master regulators of metastatic progression in proteins that were inactivated and activated by each compound treatment, respectively.
To ensure optimal fidelity of the analysis, we first focused on 32 samples whose master regulators were significantly recapitulated in H-STS xenografts (one-tailed P < 10
, Bonferroni corrected, aREA analysis; Fig. 2a) . Moreover, only sample-specific master regulator proteins that were recapitulated in the H-STS cell line, based on leading-edge analysis (Fig. 2b) , were included in the analysis. Finally, Stouffer's method was used to integrate the statistical significance of results across different drug concentrations and replicates. Results for all drugs predicted to induce tumor-checkpoint collapse in at least ten patients are shown in Fig. 5a . Complete results for all 69 metastatic GEP-NET samples are also reported ( Supplementary  Fig. 5 ), albeit relying on fewer conserved master regulators between the patient sample and the H-STS xenograft model.
As an example, consider the patient with the most statistically significant master regulator match to H-STS cells (patient 0). Six compounds were predicted to induce tumor-checkpoint collapse (Bonferroni's adjusted P < 10
, one-tailed aREA), including the class I (HDAC1/3) inhibitor entinostat, the bromodomain inhibitor I-BET151, the Nrf2-pathway-activator/NF-κ B inhibitor bardoxolone methyl, the c-Met inhibitor PHA-665752, the CDK1, 2, 4 and 6 inhibitor flavopiridol and the NMPRTase inhibitor FK866. Among all tested compounds, entinostat and I-BET151 were predicted to induce highly significant tumor-checkpoint collapse in 47% and . Enrichment score for the top 50 most de-activated (blue) and most activate (red) proteins in the metastasis is shown by the curves, and the projection of these proteins on the H-STS and the xenograft protein activity signatures-which are indicated by the color scale on the bottom of the plot-is indicated by the blue and red vertical lines, respectively. NES and Bonferroni-corrected P value (one-tailed aREA test) are indicated in the plots. 44% of metastatic samples (N = 15 and N = 14 of 32, respectively), the most of any tested compound, as well as in the H-STS xenograft ( Fig. 5a and Supplementary Fig. 5 ). They were thus selected for further validation in vivo. mTOR inhibitors and sunitinib have shown some clinical value in the treatment of GEP-NETs. Consistently, our analysis identified several mTOR/AKT/PI(3)K inhibitors, such as everolimus, AZD8055 and MK2206, among others, as strong tumor-checkpoint inhibitors (P < 10 , Bonferroni corrected, one-tailed aREA) for about 15% of GEP-NETs and as marginal inhibitors (P < 10 −5 , Bonferroni corrected) for an additional 10%-15% of the cohort. Similarly, sunitinib was identified as a strong and marginal tumorcheckpoint inhibitor for 8% and 11% of the cohort, respectively ( Fig. 5a and Supplementary Fig. 5 ).
Interestingly, entinostat modulated presentation of the cell surface markers identified as master regulators (Fig. 3c and Supplementary Note).
Drug validation in vivo.
We selected three compounds for validation in an H-STS xenograft model, including: entinostat, the drug with the strongest tumor-checkpoint collapse potential in the largest subset of GEP-NET samples, as well as in the H-STS xenograft (− log 10 P = 82 and − log 10 P = 99, respectively); tivantinib, a c-Met and microtubule inhibitor with strong activity reversal in 28% of metastatic samples (N = 9 of 32) and intermediate master regulator-activity reversal in the H-STS xenograft (− log 10 P = 8); and PDX101/belinostat, a pan-HDAC inhibitor selected as a negative control because of its complete lack of master regulator-activity reversal potential in the H-STS xenograft but with a MoA similar to entinostat (Figs. 5b and 6c) .
In vivo testing of drugs in NOD-SCID xenografts established by subcutaneous injection of H-STS cells was first conducted at Champions Oncology. Confirming our predictions, tumors treated with belinostat showed minimal tumor growth inhibition (TGI) (8% TGI at the 20 mg kg −1 dose −1 level). In contrast, entinostat showed high efficacy, with tumor regression (TR) of 68% and TGI of 112% at 25 mg kg −1 dose −1 , and TR of 58% and TGI of 110% at 50 mg kg −1 dose −1 , respectively. While treatment with entinostat was toxic at the highest dose (100 mg kg −1 ), the single surviving animal from that group showed TR of 49%. Finally, also consistent with predictions of partial master regulator-activity reversal in the xenograft model (Fig. 5c) and TGI of 28% (100 mg kg −1 dose −1 ) were observed with tivantinib (Table 1 and Fig. 5d) . The results for entinostat were independently confirmed in the mouse hospital facility at Columbia University (Fig. 5e) .
We then tested two additional drugs at the maximum tolerated dose. These included the I-BET151 bromodomain inhibitor also predicted to induce tumor-checkpoint collapse in ~44% of metastatic patients and in the H-STS model, and bardoxolone methyl, an oxidative-stress-activator/NF-κ B inhibitor predicted to induce significant tumor-checkpoint collapse in patient 0 (− log 10 P = 28) but not in the H-STS model. Weak TGI was observed for bardoxolone methyl, only at the last time point (18 d), and no significant difference was observed for I-BET151, when both were compared to vehicle control (Fig. 5e) . Lack of response was expected for bardoxolone, because it was not predicted to induce reversal of H-STS xenograft-specific master regulators and thus represented a bona fide negative control for the analysis. However, lack of response for I-BET151 was unexpected, as its predicted inversion of the xenograft's master regulators was also very strong (− log 10 P = 51, Fig. 5c ).
To assess whether the I-BET151 failure was due to differences in compound MoA in vitro and in vivo, we performed short-term pharmacodynamics measurements by profiling xenograft-derived tumors by RNA-Seq at 3 h after the third drug administration for all three tested drugs (Methods). In agreement with compound perturbations in vitro (Fig. 5c) , VIPER-based analysis of these profiles confirmed significant inhibition of HSTS xenograft master regulator-activity by entinostat but not by bardoxolone (Fig. 5f ), suggesting that VIPERinferred compound MoA in vitro was effectively recapitulated in vivo for these compounds. However, the analysis also showed that, contrary to in vitro predictions, I-BET151 did not induce significant master regulator-activity reversal in the xenograft (Fig. 5f) .
Thus, while bardoxolone may be an effective drug for some patients (for example, patient 0), its activity could not be effectively tested in the xenograft model due to master regulator differences. In contrast, I-BET151 presented significant difference between its in vitro and in vivo MoA, likely due to compound pharmacokinetics, metabolism, maximum tolerated dose or OncoTreat false-positive results. This suggests that top drugs prioritized by OncoTreat should always be validated in vivo, to assess MoA conservation. This can be done efficiently, since the number of promising drugs emerging from the analysis of a large cohort is relatively small, thus allowing efficient prioritization of drugs for follow-up clinical studies.
Discussion
Master regulator proteins represent a novel class of tumor dependencies and potential therapeutic targets that are highly enriched both in tumor-essential genes 10, 16 and synthetic-lethal pairs [11] [12] [13] . Their genetic or pharmacological inhibition induces activity reversion of the entire master regulator-protein repertoire, previously described as tumor-checkpoint collapse 8 . This provides a potential strategy (OncoTreat) for the prioritization of drugs to target tumor checkpoints.
We tested this approach in a rare class of tumors (GEP-NETs) that lack actionable mutations and remain poorly characterized [35] [36] [37] . The pipeline consists of a series of pre-computed (*) components, including a reference set of more than 13,000 tumor expression profiles representing 35 different tumor types, a collection of 28 tissue context-specific interactomes and a database of context-specific MoA for > 400 Food and Drug Administration (FDA)-approved drugs and investigational compounds in oncology. This database is obtained by perturbing at least two cell lines per tissue type-which, in a quasi-orthogonal fashion, recapitulate the top master regulator proteins for the larger proportion of tissue-matched samples in the tumor databank-with the collection of drugs and compounds. The transcriptome of the perturbed cell lines is profiled at low cost by PLATE-Seq. The process begins with the expression profile of a single patient sample, which is compared against the tumor databank to generate a tumor gene expression signature. This signature is interpreted by VIPER using a context-matched interactome to identify the set of most dysregulated proteins, which constitute the regulators of the tumor cell state-the tumor checkpoint. These proteins are then aligned against the drugs' and compounds' MoA database, to prioritize compounds able to invert the activity pattern of the tumor checkpoint. This choice was deliberate, to show applicability of the proposed methodology even to rare tumors or to tumors with few, if any, actionable mutations, a significant unmet challenge in precision oncology. Following evaluation of 107 drugs, we confirmed therapeutic potential in vivo for entinostat, a drug predicted to induce tumor-checkpoint collapse in 15 of 32 (47%) metastatic GEP-NET samples for which a suitable pre-clinical model was available, as well as 13 of 35 (37%) metastatic GEP-NET samples lacking a suitable pre-clinical model ( Supplementary Fig. 5 ). Almost all of the predicted responders (28/67), accounting for 42% of metastatic GEP-NET patients in the cohort, were from cluster M1 or M2 (Fig. 5a ). Additional drugs were identified for patients presenting alternative master regulator dependencies ( Supplementary Fig. 5 ), including inhibitors of the PI(3)K/AKT/mTOR pathway (everolimus, AZD8055, MK2206), some of which have shown some efficacy in clinical trials. Most of these belonged to cluster M3. However, lack of appropriate preclinical models prevented a more extensive validation of inferred drugs. Indeed, validation of two drugs predicted to induce patient-specific master regulator collapse was inconclusive due to differences in either patient-and xenograft-specific master regulator dependencies targeted by the drug or in vitro and in vivo MoA. For further discussion, see the Supplementary Note. The top six compounds prioritized by the analysis induced significant in vitro activity reversal of almost all patient-related master regulators, as further confirmed in vivo for entinostat. Since it is implausible that these compounds may represent specific inhibitors and agonists of each of these proteins, this confirms that master regulator proteins are organized into tightly autoregulated on/off modules (tumor checkpoints) that can be globally inactivated even by a single compound. Furthermore, induction of the established neuroendocrine marker CD56 by the top prioritized drug (entinostat) supports the hypothesis that tumor checkpoints represent key tumor state determinants and that their collapse may induce differentiation or reprogramming.
Clearly, a number of open challenges remain. For instance, in vitro screening may lead to identification of compounds with different in vivo pharmacodynamics, such as I-BET151, or those that effectively reverse master regulator activity but only in concentrations that are too high to be tolerated. This may be effectively addressed by studying compound pharmacodynamics in vivo, as shown. Finally, the proposed methodology may miss drugs inducing non-master regulator-mediated tumor toxicity. In contrast, the OncoTreat methodology is generalizable and can be applicable to any tumor for which a regulatory model and a perturbational database can be assembled, including in basket studies with drugs prioritized on the basis of their complementary coverage of a rare tumor cohort ( Fig. 5a and Supplementary Fig. 5 ).
The general logic of OncoTreat to be applied in the clinical setting is summarized in Fig. 6 . On the basis of the high reproducibility of drugs prioritized by OncoTreat-a direct result of VIPER's demonstrated reproducibility 20 -the test has been certified by the NYS CLIA laboratory and is immediately available at the Columbia University Laboratory of Personalized Genomic Medicine (see the URLs section). Furthermore, on the basis of the results of this study, the FDA approved the Investigational New Drug Application for entinostat in GEP-NETs, thus allowing further clinical validation of these results in a recently initiated clinical trial (NCT03211988). 
URLs. Columbia University Laboratory of Personalized Genomic

Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-018-0138-4.
normalized by equi-variance transformation, based on the negative binomial distribution with the DESeq R-system package (Bioconductor). At least two replicates for each condition were obtained. Differential gene expression signatures were computed by comparing each condition with plate-matched vehicle control samples using a moderated Student's t-test as implemented in the limma package from Bioconductor 43 . Individual gene expression signatures were then transformed into protein activity signatures, based on the GEP-NET regulatory network, using the VIPER algorithm 20 , as implemented in the viper package from Bioconductor.
OncoTreat analysis. Optimal alignment of drugs with tumors was obtained by analyzing the effect of the drugs on the tumor master regulators. For this, drugs were prioritized for each liver-MET sample on the basis of their ability to invert their master regulator program. Briefly, protein activity signatures after drug perturbation were obtained by first comparing the expression profile after each perturbation versus a set of vehicle control samples, including DMSO, ethanol and methanol treatments. Then, protein activity signatures in response to drug perturbation were inferred with the VIPER algorithm. Finally, the enrichment of the top/bottom 50 most differentially active proteins of each tumor on each drug-induced protein activity signature was computed by the aREA algorithm 20 . P values were estimated by the analytical approximation implemented in the aREA algorithm, which have been shown to be practically equivalent to estimations obtained by permutation of the proteins in the signature uniformly at random 20 . P values were corrected to account for multiple hypothesis testing by the Bonferroni method.
Transduction of H-STS with lentiviral shRNAs for qRT-PCR.
For qRT-PCR assays, cells were transduced with the Pepfect 14 reagent as follows. Pepfect 14 was dissolved in water to a 1 mM stock and stored at − 80 °C. Transduction conditions including cell number and Pepfect 14 concentration were optimized with a control TurboGFP Lentiviral construct from Sigma-Aldrich (MISSION SHC003V) using flow cytometry and fluorescence microscopy. Pepfect 14 in water was added to a final concentration of 30 µ M to 10 µ l of virus in 50 µ l total volume of serum-free medium, mixed immediately, and incubated at room temperature for 1 h to allow complex formation. H-STS cells were plated at 50,000 cells per well of a 24-well plate in 500 µ l of serum-free growth medium without antibiotics, and 50 µ l of the virus complex was added to cells and mixed by swirling (multiplicity of infection ~1:100). Cells were incubated at 37 °C for 1.5 h, and then 60 µ l of FBS was added. Cells were incubated for another 24 h at 37 °C before being harvested for qRT-PCR. ) and lysed with Cells-to-cDNA II Lysis Buffer (ThermoFisher Scientific). Following DNAse treatment (Cells-to-cDNA II kit) of cell lysates and inactivation of DNAse, total RNA was subjected to cDNA synthesis using qScript cDNA Synthesis Kit (Quanta Biosciences) followed by qPCR using Power SYBR Green Master Mix (ThermoScientific), according to the manufacturer's instructions following optimization.
Long-term viability assays following shRNA transduction and puromycin selection. Optimal starting cell numbers for these assays were determined by a growth curve, and the optimal number of days (three days) to allow efficient puromycin expression was determined by a time course over seven days. H-STS, KRJ-1 or NCI-H716 cells at 50,000 cells in 500 µ l plain medium per well in 24-well plates were treated with 10 µ l of appropriate shRNA lentivirus alone and incubated at 37 °C for 1 h. Then 60 µ l of plain FBS was added and incubation was continued for 3 days. At this time, cells were recovered and re-plated at 50,000 cells per well in 500 µ l of fresh complete growth medium containing puromycin to a final concentration of 0.8 µ g ml −1 for H-STS and KRJ-1 cells (and 1.0 µ g ml −1 for NCI-H716). Control lentiviral shRNAs were SHC202V and SHC007V. After three more days of growth with puromycin, cells were resuspended and an equal aliquot of cells from each well was used to determine cell viability using the Cell-Titer-Glo ATP Assay (Promega). Viability was expressed as a percentage of the average of all controls, setting the value from untransfected puromycin-treated cells as the baseline. Table 7 . Cells were washed once with PBS containing 0.1% BSA and 5 mM EDTA, resuspended in the wash buffer and analyzed. The gating strategy is described in Supplementary Fig. 6 .
Agent efficacy evaluation.
All experiments using animals were performed according to protocols approved by the Institutional Animal Care and Use Committee (IACUC) at Columbia University Medical Center. NOD.Cg-Prkdc scid
Il2rg
tm1Wjl /SzJ mice 8 weeks of age or older were inoculated subcutaneously with 10 6 H-STS cells in 200 µ l of 25% LDEV-free Matrigel in PBS. All test agents were formulated according to the manufacturer's specifications. Beginning at day 0, tumor dimensions were measured twice weekly by digital caliper and data, including individual and mean estimated tumor volumes (mean TV ± s.e.m.), were recorded for each group. Tumor volume was calculated using the formula: TV = width × length × π /2j.
Tumor growth inhibition and RECIST. At study completion, percentage of TGI (%TGI) values were calculated and reported for each treatment group (T) versus the control (C) using initial (i) and final (f) tumor measurements by the formula:
. Individual mice reporting a tumor volume > 120% of the day 0 measurement are considered to have progressive disease. Individual mice with neither sufficient shrinkage nor sufficient tumor volume increases are considered to have stable disease. Individual mice reporting a tumor volume ≤ 70% of the day 0 measurement for two consecutive measurements over a seven-day period are considered partial responders. If the partial response persisted until study completion, percentage TR (%TR) is determined using the formula: %TR = (1 − T f /T i ) × 100; a mean value is calculated for the entire treatment group. Individual mice lacking palpable tumors for two consecutive measurements over a seven-day period are classified as complete responders. All data collected in this study were managed electronically and stored on a redundant server system.
Drug pharmacodynamics evaluation by expression profile analysis.
Subcutaneous tumors were resected at 3 h after the third application of the drug and snap-frozen in N 2 . Total RNA was isolated as described previously and profiled by 30M-SE RNA-Seq. Gene expression signatures in response to drug perturbation in vivo were computed by comparison against gene expression profiles obtained from xenografts growing subcutaneously in matched untreated animals. The corresponding protein activity signatures were inferred with the VIPER algorithm 20 , using the GEP-NET regulatory network model. The effect of the compounds on the MET master regulator program in vivo was evaluated by computing the enrichment of the top/bottom 50 most differentially active proteins in the tumors, on the drug-induced protein activity signature obtained from in vivo perturbation experiments. Enrichment analysis was performed with the aREA algorithm 20 .
Statistical analysis. Enrichment analysis, including model matching based on master regulator conservation and OncoTreat analysis, was computed by the aREA algorithm and statistical significance was estimated by the analytical approximation implemented in the algorithm 20 . Cluster reliability scores as well as their statistical significance were estimated by the aREA algorithm, and compared by one-sided paired U-test. Statistical significance for adjusted Rand index was estimated by permutation test. Statistical significance for the association of gastrin, glucagon, insulin, somatostatin and vasoactive intestinal polypeptide expression with the E and A clusters was estimated by ANOVA. Significance values for differential gene expression after shRNA-mediated knockdown and cell viability were estimated by two-factor ANOVA using a one-sided test. P values were adjusted to account for multiple hypothesis testing by Benjamini 
Data exclusions
Describe any data exclusions. Only 3 primary NET samples were removed from the analysis of MET-MRs because they could not be reliably assigned to any of the clusters (Fig. 1b) .
Replication
Describe whether the experimental findings were reliably reproduced. All attempts for replicating the experiments were sucessful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Animals were randomly allocated in the different experimental arms.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Investigators collecting tumor size measurements were blind to the treatment administered to each experimental arm. All the data analysis was performed by systematic computational pipelines.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly.
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. p values) given as exact values whenever possible and with confidence intervals noted A summary of the descriptive statistics, including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
